Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetrahydrocannabinol + cannabinol
- Development stage
- Unknown
- Lead developer
- Tilray
- Modality
- Small Molecules
- Administration
- Oral, Sublingual, Inhalation
01
Overview
Tetrahydrocannabinol (THC) and cannabinol (CBN) are cannabinoids derived from the *Cannabis sativa* plant. THC is the primary psychoactive constituent and acts as a partial agonist at the cannabinoid CB1 and CB2 receptors. CBN is a non-enzymatic oxidation product of THC; it possesses a lower affinity for CB1 and CB2 receptors compared to THC but is frequently utilized for its purported sedative effects. The combination is primarily developed and marketed within the medical cannabis industry for the management of insomnia and sleep disturbances, leveraging a potential synergistic effect often referred to as the entourage effect to promote sleep without the high intensity of THC alone. While not currently an FDA-approved pharmaceutical drug product, standardized formulations are widely available in legal medical cannabis markets.
- Brand names
- MidnightZzz-BombCBN:THC 1:1 Oil
- Other names
- THC + CBNDelta-9-THC + CBN
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on tetrahydrocannabinol + cannabinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetrahydrocannabinol + cannabinol.